In 2013, itolizumab received approval in India as a safe and effective treatment for plaque psoriasis. In aGVHD, steroid-insensitive CD6-high T cells contribute to gastrointestinal inflammation ...

Equillium is on the cusp of taking CD6-targeting antibody itolizumab into phase 3 testing for GvHD, a potentially life-threatening complication of transplant procedures, and is waiting for results ...

Itolizumab demonstrated clinical efficacy after ... experts in the field of inflammatory bowel disease (IBD). "The CD6-ALCAM pathway is elevated in gastrointestinal inflammation and is associated ...

Equillium (NASDAQ:EQ – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on ...